ArticleMolecular biology reports2026
Yam glycoprotein mediated the immunomodulation of macrophages by targeting TLR4.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundYam is a medicinal plant and previous studies have demonstrated that the yam glycoprotein (GLP1) possessed immunomodulatory bioactivity. However, how GLP1 exerted immunomodulatory effect and the molecular mechanism is unclear. To investigate the underlying mechanisms, the immunoregulation of GLP1 on macrophages are examined. METHODS AND
resultsThe composition of GLP1 was investigated using high-performance liquid chromatography (HPLC) and UV visible spectrophotometer (UV-Vis). The activity of macrophages was detected, and the effects of GLP1 on macrophages were studied using immunofluorescence, flow cytometry, Enzyme-linked immunosorbent assay (ELISA), and Western blotting. Results indicated that GLP1, as a biomolecule, contained abundant monosaccharides and possessed O-glycopeptide bonds. GLP1 bound to pattern recognition receptors (PRRs) and was internalized by macrophages via toll-like receptor 4 (TLR4), thereby exerting its immunomodulatory effects. Further experimental studies revealed that GLP1 promoted RAW264.7 cells proliferation by advancing cells from G0/G1 phase to S phase. Additionally, GLP1 stimulated the secretion of reactive oxygen species (ROS) from mitochondria and induced macrophage polarization toward the M1 phenotype.
conclusionGLP1 is a functional protein and has the capacity to regulate macrophages immune responses via the TLR4/NF-κB pathway. The findings highlighted the potential of GLP1 might as a dietary immunostimulant at the molecular level.
Indexed as
Identifiers
42313284What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.